Press Releases



Mediclinic Intnl plc - Directorate Change

21/02/2020
RNS Number : 6654D
Mediclinic International plc
21 February 2020
 

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company", or the "Group")

 

 

21 February 2020

 

DIRECTORATE CHANGE

 

Following the previous announcement made on 16 January 2020, the Company confirms that Mr Seamus Keating, who serves as an independent non-executive director, will step down from the Board of Mediclinic on 31 March 2020. Mr Keating's intention to retire from the Board was announced subsequent to his appointment as Chief Executive Officer of First Derivatives plc with effect from 15 January 2020. Mr Keating will also resign from all Board subcommittees at that time which include the Audit and Risk Committee, Remuneration Committee and Clinical Performance and Sustainability Committee.

 

The Board will shortly commence a process to identify a suitable replacement for Mr Keating, with an announcement to follow accordingly.

 

This announcement is made in accordance with the requirement of LR 9.6.11.

 

About Mediclinic International plc

 

Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates.

 

The Group's core purpose is to enhance the quality of life.

 

Its vision is to be the partner of choice that people trust for all their healthcare needs.

 

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

 

As at 1 February 2020, Mediclinic comprised 77 hospitals, five sub-acute hospitals, 14 day case clinics and 22 outpatient clinics. Hirslanden operated 17 hospitals, two day case clinics and three outpatient clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations included 53 hospitals (three of which in Namibia), five sub-acute hospitals and 10 day case clinics (four of which operated by Intercare) across South Africa, and more than 8 500 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 19 outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.

 

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE Ltd ("JSE") in South Africa and the Namibian Stock Exchange ("NSX") in Namibia.

 

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

 

For further information, please contact:

 

Company Secretary, Link Company Matters Limited

Caroline Emmet

+44 (0)20 7954 9569

 

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

 

Media queries

FTI Consulting

Ben Atwell/Ciara Martin - United Kingdom

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

 

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com 

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAPPUACPUPUGQU